Boston, Massachusetts 2021-11-30 06:30:52 –
NSAntibody treatment, which delivers targeted doses of chemotherapy directly to cancer cells, has shrunk tumors in patients with advanced ovarian cancer and has achieved key goals in late-stage clinical trials, treatment maker Immunogen said Tuesday. ..
Based on the research results, the immunogen will submit a treatment (so-called antibody drug conjugate) for accelerated approval by the Food and Drug Administration in early 2022. If approved, it will be the first full ownership of the 40-year-old company. Cancer treatments to reach the market.
Immunogen hits primary goal of shrinking tumors in ovarian cancer patients Source link Immunogen hits primary goal of shrinking tumors in ovarian cancer patients